Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation

Acute Leukemia Clinical Trial

Official title:

Phase 1/2 Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells Infusion for Promotion of Engraftment and Prevention of an Graft Rejection and Graft-versus-Host Disease After Unrelated Hematopoietic Stem Cell Transplantation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00823316
• Other study ID #: MP-CR-MSC003
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: January 13, 2009
• Last updated: April 20, 2012
• Start date: August 2008
• Est. completion date: February 2010

Study information

• Verified date: April 2012
• Source: Medipost Co Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Korea: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and prevention of graft rejection and Graft-Versus-Host Disease after unrelated hematopoietic stem cell transplantation for children with acute leukemia.

Description:

• Hematopoietic stem cell transplantation (HSCT) is a procedure in which progenitor cells capable of reconstituting normal bone marrow function are administered to a patient. This procedure has been used to treat adults and children with life-threatening hematological malignancies and congenital immunodeficiency disorders.

• In HSCT, therapeutic goal is an elimination of disease and enrichment of regenerating capacity to achieve engraftments resulting in continued generation of functional blood elements from the engrafted living cells. Transplantation of unrelated hematopoietic stem cells originating either from adult bone marrow or from peripheral blood often leads to graft-versus host-disease (GvHD), opportunistic infections and graft failure after transplantation.

• In HSCT, MSC have been used as a therapy for GvHD and other complications. The aim of MSC infusions in HSCT is to use the cells' immunomodulatory effects to promote engraftment and to reduce the immunological reactions giving rise to GvHD.

• There is a growing interest in co-transplantation of MSC and HSC to improve the donor outcome in the unrelated HSCT condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: February 2010
• Est. primary completion date: February 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 2 Years to 19 Years

Eligibility

Inclusion Criteria:

1. Patient age 2~19 years old with plan to have unrelated hematopoietic stem cell transplantation with acute leukemia

2. Patient never has an experience of hematopoietic stem cell transplantation

3. Patient must have an acute leukemia with a complete remission.

4. Patients must have an ECOG 0~2.

5. No moderate or sever organ dysfunction : Ejection fraction > 45%; Creatinine <2.0 mg/ml; Serum bilirubin < 2 mg/ml; AST/ALT < 200 IU/L.

6. Patient must not have an transplantation with different source of hematopoietic stem cell such as bone marrow and cord blood.

7. Patient must not have an infection needed an administration of non-oral antibiotics.

8. No active severe infection derived form virus or fungus.

9. Each patient / patient's guardian must sign written informed consent.

Exclusion Criteria:

1. Patient has previously received hematopoietic stem cell transplantation.

2. Patient plans to have a related hematopoietic stem cell transplantation.

3. Patient has a severe internal disease.

4. Patient has enrolled another clinical trial study within last 4 weeks.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acute Leukemia

Intervention

Biological:
• Human umbilical cord blood-derived mesenchymal stem cells
1x1,000,000 hMSC/kg, IV after unrelated HSCT
• Human umbilical cord blood-derived mesenchymal stem cells
5x1,000,000 hMSC/kg, IV after unrelated HSCT

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Medipost Co Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate		28 and 100 days	No
Secondary	- AGVHD grade		100 days	No